EXSCIENTIA
21.7.2021 10:02:06 CEST | Business Wire | Press release
Exscientia , an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics （Apeiron） , a Shanghai based company focused on novel oncology drugs, announced today a strategic research and development collaboration agreement. The collaboration will leverage the patient-centric AI-first capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. All pipeline products will be equally owned and Exscientia holds an equity stake in Apeiron.
This expanded collaboration follows the successful design of multiple selective CDK7 compounds. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.
“Based on what they have already achieved , Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far,” stated Dr. Mingxi Li, President of GT Apeiron Therapeutics. “We have been incredibly impressed by the combined power of the AI design and use of patient data to optimize and select molecules that are more likely to give positive effects in the clinic. This joint venture is a significant step in building GT Apeiron’s valuable and robust pipeline of CDK inhibitor drugs and substantially accelerates our early-stage output and progression towards being a clinical stage biotech company.”
“We are driven to bring drugs to market that make a difference for patients,” says Andrew Hopkins, chief executive officer of Exscientia. “Apeiron bring a focus and an expertise on the biological basis of multiple cancers and helps us to create better drugs for better outcomes in the clinic and beyond. This collaboration has already proven to be capable of delivering potential drug candidates with promising patient-relevant data, and we look forward to extending that into a portfolio of multiple clinical assets.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai Social media: Twitter @exscientiaAI . LinkedIn https://www.linkedin.com/company/ex-scientia/
About GT Apeiron Therapeutics
GT Apeiron Therapeutics is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs. To learn more, visit http://www.apeiron-bio.com/ Social media: LinkedIn https://www.linkedin.com/company/gt-apeiron-therapeutics/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify Launches Global Air Travel Fraud Report Revealing Where Booking-Stage Pressure Is Most Concentrated22.4.2026 14:00:00 CEST | Press release
Q1 2026 analysis shows significant variation in prevented fraud rates by origin city, with higher concentrations across parts of Latin America, Africa, the Middle East, and South & Southeast Asia Accertify, a leading unified risk decisioning platform provider, today announced the release of its Global Air Travel Fraud Report: Q1 2026, a quarterly analysis examining how fraud risk in airline bookings varies by route origin across global markets. Based on more than 180 million airline booking transactions processed between January and March 2026, the report analyzes fraud rates by departure city as a proxy for route origin, offering airlines a practical view of where fraud prevention systems are intervening most frequently at the point of booking. The Q1 2026 findings show that fraud risk in airline bookings is unevenly distributed across markets, with meaningful differences emerging by region and by origin city. Routes originating in North America and Australia continue to exhibit consi
NetApp Strengthens its Collaboration with Google Cloud on Unified Google Cloud Storage for File and Block22.4.2026 14:00:00 CEST | Press release
Announced at Next ‘26, Flex Unified service for Google Cloud NetApp Volumes is now generally available NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today shared new innovations that help customers better leverage their enterprise data, by tapping into the benefits of AI with Google Cloud. Enterprises want to use their existing data for AI, but moving and managing that data across multiple environments is complex, slow, and expensive. NetApp is simplifying this with Google Cloud. With Google Cloud NetApp Volumes, customers can run enterprise applications, databases, and AI workloads in the cloud without rearchitecting or rebuilding their environments. “Customers can move their enterprise data, whether block or file, into Google Cloud NetApp Volumes easily, and once it’s there, they can use Google Cloud services, including for AI, directly on that data without needing to move or duplicate it again,” said Pravjit Tiwana, Senior Vice President and General Manager of
NetApp Partners with Google Cloud to Adopt AI-Driven Operations22.4.2026 14:00:00 CEST | Press release
Google Gemini Enterprise drives productivity for NetApp sales and product development NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a strategic evolution in its partnership with Google Cloud, which has enabled enterprises to drive AI innovation with their own data stored in the NetApp data platform. After seeing the productivity and innovation benefits customers experienced using Gemini Enterprise integrated with their data in Google Cloud NetApp Volumes, NetApp has adopted Gemini Enterprise to help increase productivity in its internal product development and sales operations. With the adoption of Google Cloud AI technologies, NetApp is expanding its leadership in enterprise-grade AI innovation, not just enabling AI workloads but acting as an AI practitioner. NetApp customers will benefit from the AI-powered gains in productivity and innovation. “AI is an imperative for enterprise success, and NetApp is committed to leading by example,” said Césa
ExaGrid Named a Finalist for the Storage Awards 202622.4.2026 14:00:00 CEST | Press release
ExaGrid Product Line, Partner Program, and Team Nominated in 16 Categories for “The Storries XXIII” ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 16 categories for the 23rd annual Storage Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422235829/en/ ExaGrid has become a finalist in the following categories: Storage Innovator of the Year Immutable Storage Company of the Year Storage Industry Champion – Commercial Storage Industry Champion – Marketing Channel Excellence Award AI Data Storage Innovator of the Year Cyber Resilient Storage Company of the Year Ransomware Product of the Year Data Protection Company of the Year Enterprise Backup Hardware Vendor of the Year Object Storage Vendor of the Year Storage Optimisation Compan
Samsung Biologics Union Holds First Rally, Warns of May 1 Strike22.4.2026 13:56:00 CEST | Press release
Union estimates about 2,200 participants at one-hour event outside Bio Campus 1 Samsung Biologics’ labor union held its first rally on Tuesday and said it would move ahead with a strike on May 1 if management continues to reject meaningful talks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422754766/en/ Union members gather at a rally organized by the Samsung Biologics labor union outside Bio Campus 1 in Songdo, Incheon, on April 22, ahead of a planned May 1 strike. The rally, held for about an hour outside the main gate of the company’s Bio Campus 1 in Songdo, drew about 2,200 participants, according to the union. The event marks an escalation in a labor dispute that union leaders say is no longer limited to a small number of bargaining items, but instead concerns broader questions about accountability and decision-making within the company. Park Jaesung, chair of the Samsung Biologics union, said management had faile
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom